Hideaki Kanazawa
Overview
Explore the profile of Hideaki Kanazawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
78
Citations
1396
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Soma Y, Tohyama S, Kubo A, Yamasaki T, Kabasawa N, Haga K, et al.
iScience
. 2024 Nov;
27(11):111234.
PMID: 39569381
Cardiac regenerative therapy using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) has been applied in clinical settings. Herein, we aimed to investigate the metabolic profiles of hiPSC-CM grafts. RNA sequencing...
2.
Akagi T, Hara H, Kanazawa H, Fukui S, Hashimoto Y, Iguchi Y, et al.
Circ J
. 2024 May;
88(9):1391-1397.
PMID: 38735702
Background: The Amplatzer PFO Occluder was approved for marketing in Japan in May 2019, and the Amplatzer PFO Occluder Japan Post-marketing Surveillance (PFO Japan PMS) study was initiated in December...
3.
Kobayashi H, Tohyama S, Ichimura H, Ohashi N, Chino S, Soma Y, et al.
Circulation
. 2024 Apr;
150(8):611-621.
PMID: 38666382
Background: The clinical application of human induced pluripotent stem cell-derived cardiomyocytes (CMs) for cardiac repair commenced with the epicardial delivery of engineered cardiac tissue; however, the feasibility of the direct...
4.
Iwata J, Kodaira M, Kishino Y, Anzai A, Kanazawa H, Hayashida K, et al.
JACC Case Rep
. 2024 Mar;
29(5):102221.
PMID: 38464796
A 24-year-old woman with chronic active Epstein-Barr virus (CAEBV) infection successfully underwent coronary artery bypass grafting for triple coronary arteries with chronic total occlusion and aneurysms. This case underscores the...
5.
Moriwaki T, Tani H, Haga K, Morita-Umei Y, Soma Y, Umei T, et al.
Cell Rep Methods
. 2023 Dec;
3(12):100666.
PMID: 38113855
Three-dimensional (3D) cultures are known to more closely mimic in vivo conditions compared with 2D cultures. Cardiac spheroids (CSs) and organoids (COs) are useful for 3D tissue engineering and are...
6.
Kimura M, Shinada K, Miura K, Endo J, Tsuruta H, Itabashi Y, et al.
CJC Pediatr Congenit Heart Dis
. 2023 Nov;
1(5):241-244.
PMID: 37969434
The prevalence of atrial tachyarrhythmia is high in patients with atrial septal defect (ASD), and catheter ablation (CA) is often performed before percutaneous ASD closure. We aimed to clarify the...
7.
Miura K, Yagi R, Miyama H, Kimura M, Kanazawa H, Hashimoto M, et al.
EClinicalMedicine
. 2023 Sep;
63:102141.
PMID: 37753448
Background: Atrial septal defect (ASD) increases the risk of adverse cardiovascular outcomes. Despite the potential for risk mitigation through minimally invasive percutaneous closure, ASD remains underdiagnosed due to subtle symptoms...
8.
Sekine O, Kanaami S, Masumoto K, Aihara Y, Morita-Umei Y, Tani H, et al.
Stem Cell Reports
. 2023 Sep;
18(10):1925-1939.
PMID: 37738969
Monitoring cardiac differentiation and maturation from human pluripotent stem cells (hPSCs) and detecting residual undifferentiated hPSCs are indispensable for the development of cardiac regenerative therapy. MicroRNA (miRNA) is secreted from...
9.
Tani H, Kobayashi E, Yagi S, Tanaka K, Kameda-Haga K, Shibata S, et al.
Biomaterials
. 2023 Jun;
299:122174.
PMID: 37285642
Although the extracellular matrix (ECM) plays essential roles in heart tissue engineering, the optimal ECM components for heart tissue organization have not previously been elucidated. Here, we focused on the...
10.
Kishino Y, Tohyama S, Morita Y, Soma Y, Tani H, Okada M, et al.
J Card Fail
. 2023 Apr;
29(4):503-513.
PMID: 37059512
Heart transplantation (HT) is the only definitive treatment available for patients with end-stage heart failure who are refractory to medical and device therapies. However, HT as a therapeutic option, is...